An Evaluation of Estimating Methods for the Maximum Tolerated Dose (MTD) in Phase I Clinical Trial
碩士 === 國立成功大學 === 統計學系 === 102 === Phase I clinical trials are the first application to humans in the clinical development of new drug agents. The main purpose of the phase I clinical trials is to understand the dose range of new drugs, that is to identify the Maximum Tolerated Dose (MTD) and to be...
Main Authors: | Yi-LiChen, 陳宜莉 |
---|---|
Other Authors: | Mi-Chia Ma |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/37156110748754497058 |
Similar Items
-
The 3 +3 Design And Modified Toxicity Probability Interval Designs For The Maximum Tolerated Dose (MTD) In Phase I Clinical Trial
by: Fang-Yu Wen, et al.
Published: (2018) -
Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
by: Ami Takahashi, et al.
Published: (2021-03-01) -
Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials [version 3; referees: 3 approved, 1 approved with reservations]
by: David C. Norris
Published: (2017-07-01) -
Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials [version 2; referees: 2 approved, 1 approved with reservations]
by: David C. Norris
Published: (2017-03-01) -
The study of the maximum tolerated dose in phase I oncology clinical trials
by: Yu-ChiehHuang, et al.
Published: (2011)